Small Molecules
Total Trials
25
As Lead Sponsor
22
As Collaborator
3
Total Enrollment
2,528
NCT00827138
Study Safety and Preliminary Efficacy of DCC-2036 in Patients With Leukemias (Ph+ CML With T315I Mutation)
Phase: Phase 1
Role: Lead Sponsor
Start: Mar 31, 2009
Completion: Jan 31, 2013
NCT02228811
A Study of DCC-2701 in Participants With Advanced Solid Tumors
Start: Jun 30, 2014
Completion: Jan 31, 2018
NCT02571036
A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies
Start: Nov 30, 2015
Completion: Apr 29, 2022
NCT02824575
Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer
Role: Collaborator
Start: Jul 31, 2016
Completion: Dec 27, 2021
NCT03069469
Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor
Phase: Phase 1/2
Start: Feb 16, 2017
Completion: Aug 31, 2028
NCT03353753
Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies
Phase: Phase 3
Start: Feb 27, 2018
Completion: May 11, 2022
NCT03601897
A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors
Start: Oct 25, 2018
Completion: May 23, 2022
NCT03717415
A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors
Start: Jan 2, 2019
Completion: Nov 1, 2022
NCT03673501
A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib
Start: Feb 8, 2019
Completion: Dec 31, 2025
NCT04892017
A Phase 1/2 Study of Inlexisertib (DCC-3116) in Patients With RAS/MAPK Pathway Mutant Solid Tumors
Start: Jun 15, 2021
NCT04530981
A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients with Advanced GIST
Start: Sep 22, 2021
Completion: Jul 29, 2024
NCT05059262
Study of Vimseltinib for Tenosynovial Giant Cell Tumor
Start: Oct 14, 2021
Completion: Jul 31, 2026
NCT05080621
Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST)
Start: Nov 30, 2021
Completion: May 31, 2027
NCT05957367
A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies
Start: Sep 28, 2023
Completion: Mar 31, 2029
NCT05734105
A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib
Start: Dec 13, 2023
Completion: Dec 31, 2027
NCT06287463
Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway
Start: May 14, 2024
Completion: Aug 31, 2027
NCT06619275
Ripretinib (QINLOCK®) According to Current SmPC
Phase: N/A
Start: Oct 17, 2024
Completion: Nov 30, 2027
NCT06619561
A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
Phase: Phase 2
Start: Nov 21, 2024
Completion: Oct 31, 2029
NCT06630234
A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)
Start: Dec 10, 2024
Completion: May 31, 2028
NCT06966024
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
Start: Aug 27, 2025
Completion: Feb 28, 2029
NCT07075471
Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib
Start: Aug 31, 2025
Completion: Sep 30, 2027
NCT07158398
Evaluate the Effect of Vimseltinib on the Pharmacokinetics of a BCRP and OATP1B1 Substrate
Start: Oct 31, 2025
Completion: Jun 30, 2026
NCT07158411
Evaluate the Effect of Vimseltinib on Organic Cation Transporter 2 (OCT2)
Start: Nov 30, 2025
NCT07104032
Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)
Completion: Dec 31, 2029
Loading map...